RecruitingNCT06599957

Innovative Drug Delivery Nanophotonic Platform for Implementation of Sarcoma Therapy

Sponsor

Istituto Ortopedico Rizzoli

Enrollment

30 participants

Start Date

Aug 30, 2024

Study Type

OBSERVATIONAL

Conditions

Bone and Soft Tissue Tumors

Summary

DEEPLY aims to improve sarcoma therapy by the development of an innovative nanophotonic delivery approach to be applied in the future as an integrated local therapy for patients with inoperable tumors or with oligometastases. The major aim of the project is the development of innovative nanocarriers loaded with chemotherapeutic agents, whose delivery will be improved by the use of an optic fiber (optoporation). After the synthesis, and characterization of NPs, a prototype will be produced and preclinically validated on patient-derived biological material. This wide comprehensive methodological approach will ensure the obtainment of robust data to be faster exploited toward clinical applications.

Eligibility

Min Age: 2 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting tissue samples from patients with sarcomas (cancers of the bone or soft tissue) to develop a new technology called a nanophotonic drug delivery platform — a cutting-edge system designed to deliver cancer treatment drugs more precisely to tumour cells. **You may be eligible if...** - You have been diagnosed with a soft tissue sarcoma or bone sarcoma (including osteosarcoma) - You are undergoing surgery or a biopsy for your sarcoma - You may have had or are currently receiving chemotherapy, radiation, or targeted therapy - You are willing to sign an informed consent form - If enrolling at the adult centre (IRST), you must be over 18 years old **You may NOT be eligible if...** - You do not have a sarcoma diagnosis - You have been diagnosed with more than one primary cancer at the same time Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.